Merck KGaA invests Eur250 million in Swiss manufacturing and R&D facility
German company Merck KGaA is investing Euro 250 million in a Swiss biologics facility that bridges manufacturing and research.
The 15,700 square meter Biotech Development Center will be built near Merck’s current manufacturing site in Corsier-sur-Vevey, employing a cross-functional team of around 250 people.
“This investment… reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
Merck said the facility will be equipped with continuous manufacturing and laboratory automation to help accelerate development timelines and will have a flexible-by-design infrastructure that can adapt to evolving technology.
Construction is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022 following validation by regulatory authorities, Merck said.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance